Investor Relations

Home / About us / Investor Relations

Make Water Safe

Legionellosis (Legionnaires’ disease) is a severe respiratory disease like COVID-19, SARS, MERS, or influenza pneumonia. Since the year 2000, Legionnaire’s disease cases have grown by 500-700%. 

rqmicro AG is a life science and tech startup founded in 2013. Since its spin-off from ETH Zurich (Switzerland), the company invested CHF 12 mio., has built traction for its patented technology platform and already generates revenue with industry leaders. rqmicro aims to protect consumers worldwide from microbiologically contaminated water and food and its first commercial application focuses on the detection of Legionella bacteria in water samples.  

The rapid detection platform, suitable for lab and on-site tests, gives reliable and accurate results in less than 2 hours, outperforming the existing standard tests which take 10 days to perform a less accurate analysis. The first US-accreditation for the Legionella rapid test is expected by mid-2020, which enables further expansion in the USD 4.5bn addressable market within industrial microbiology.

Upcoming Series B Financing Round

rqmicro intends to raise a Series B financing round to finance market and product development. Major contributions to the round are already committed.

Contact rqmicro investor relations contact below for more information.

Company Contact

rqmicro AG
Investor Relations:
Phone: 044 512 51 10